Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2010 - 2026)

Lineage Cell Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $45.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 5.45% year-over-year to $45.3 million; the TTM figure through Mar 2026 stood at $45.3 million (down 5.45% YoY), while the FY2025 annual figure was $46.0 million, up 12.06% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $45.3 million, down from $46.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $78.1 million in Q1 2022, with the low at $11.4 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $33.9 million (2023), against an average of $38.3 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 80.21% in 2023, then jumped 182.03% in 2024.
• Lineage Cell Therapeutics' Cash & Equivalents stood at $11.4 million in 2022, then surged by 163.63% to $29.9 million in 2023, then surged by 37.02% to $41.0 million in 2024, then climbed by 12.06% to $46.0 million in 2025, then declined by 1.5% to $45.3 million in 2026.
• Business Quant data shows LCTX's Cash & Equivalents at $45.3 million in Q1 2026, $46.0 million in Q4 2025, and $32.2 million in Q3 2025.